Gland Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Results
Gland Pharma share price Rs 2,855.20 on 16 September 2026, down 1.39%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 317.00 crore. Q2 FY26 base a profit of Rs 184.00 crore.
Quick Answer
The Gland Pharma Q2 results date for FY27 is not confirmed, and Gland Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 1,487.00 crore in revenue and a profit of Rs 184.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Gland Pharma Q2 results FY27 announcement is the next scheduled earnings event for Gland Pharma Ltd., Gland Pharma manufactures and supplies generic injectable and complex pharmaceutical formulations for regulated and emerging markets globally.. The stock traded at Rs 2,855.20 on the NSE on 16 September 2026, down 1.39% from the previous close of Rs 2,895.50, about 6.1% below its 52-week high of Rs 3,042.00 and 81.4% above its 52-week low of Rs 1,573.60.
What makes the Gland Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 1,487.00 crore of revenue and a profit of Rs 184.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 1,800.00 crore and a profit of Rs 317.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Gland Pharma Q2 Results FY27 Date?
The Gland Pharma Q2 results date for FY27 is not confirmed. As of 16 September 2026, Gland Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Gland Pharma Q2 results date becomes public through that filing rather than through any advance announcement.
The Gland Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Gland Pharma.
Gland Pharma Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Gland Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Gland Pharma. The Gland Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.
Gland Pharma Q2 results for the September 2026 quarter follow a period of steady revenue growth on a standalone comparison basis. Revenue rose from Rs 1,506 crore in June 2025 to Rs 1,487 crore in September 2025, then climbed to Rs 1,695 crore in December 2025, Rs 1,743 crore in March 2026 and Rs 1,800 crore in June 2026. Ahead of Gland Pharma Q2 results, this shows a consistent step-up in the injectable formulations business over the last three reported quarters after a mild dip in September 2025. Gland Pharma Q2 results for the September 2026 quarter will be measured against this recently improved revenue trajectory, with the Rs 1,800 crore June 2026 print serving as the most recent base for comparison as the company reports its next quarterly update.
Operating margin at Gland Pharma moved from 24 percent in June 2025 down to a period low of 21 percent in September 2025, before recovering to 26 percent in December 2025, a peak of 29 percent in March 2026 and 27 percent in June 2026. Net profit followed a broadly similar path, from Rs 215 crore in June 2025 to Rs 184 crore in September 2025, Rs 261 crore in December 2025, Rs 367 crore in March 2026 and Rs 317 crore in June 2026. It is worth noting that March 2026 included an unusually large other income figure of about Rs 111 crore, roughly double the typical run rate, which boosted that quarter’s profit beyond what operating performance alone would suggest. Ahead of Gland Pharma Q2 results for the September 2026 quarter, the underlying operating trend, with margin recovering from the September 2025 low to the 27 to 29 percent range, is the more reliable signal than the March 2026 profit figure on its own.
Gland Pharma trades at a price to earnings multiple of about 41.7, with book value near Rs 629 per share, return on equity of roughly 10.7 percent, return on capital employed near 15.1 percent and a dividend yield of about 0.69 percent. The key data-quality caveat ahead of the September 2026 quarter is the unusually large other income of around Rs 111 crore booked in March 2026, nearly double the normal run rate, which materially boosted that quarter’s profit and should not be treated as a clean base for comparison. Gland Pharma Q2 results for the September 2026 quarter should therefore be assessed against the underlying operating trend rather than the March 2026 headline profit figure. With that caveat flagged, Gland Pharma Q2 results otherwise reflect a healthy operating recovery, and Gland Pharma Q2 results will show whether margins can sustain the 27 to 29 percent range seen in the most recent quarters.
Check Gland Pharma Ltd. Live Fundamentals on the Univest Screener
Gland Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Gland Pharma Ltd. reported revenue of Rs 1,800.00 crore in Q1 FY27, up 19.52% from Rs 1,506.00 crore in Q1 FY26, and a profit of Rs 317.00 crore at the net level, up 47.44% from Rs 215.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 3.27% over the March 2026 quarter figure of Rs 1,743.00 crore, and net profit was down 13.62% from Rs 367.00 crore in Q4 FY26. Operating margin stood at 24.0% in Q1 FY27 against 21.0% in the September 2025 quarter, which is the comparison the Gland Pharma Q2 results print will be read against.
Q2 FY26 Base: The Comparison Gland Pharma Q2 Results FY27 Must Beat
Gland Pharma Ltd. reported revenue of Rs 1,487.00 crore and a profit of Rs 184.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Gland Pharma Q2 results preview.
Net profit in that base quarter was below the Rs 317.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 1,487.00 crore sits below the Rs 1,800.00 crore of the June 2026 quarter, which frames how much sequential movement the Gland Pharma Q2 results print needs to show growth.
Gland Pharma Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 1,487.00 | 184.00 |
| Q3 FY26 (Dec 2025) | 1,695.00 | 261.00 |
| Q4 FY26 (Mar 2026) | 1,743.00 | 367.00 |
| Q1 FY27 (Jun 2026) | 1,800.00 | 317.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Gland Pharma Q2 results preview uses.
Revenue across those four quarters ranged from Rs 1,487.00 crore to Rs 1,800.00 crore, and net profit from Rs 184.00 crore to Rs 367.00 crore. That spread is the honest context for the Gland Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Gland Pharma Q2 Results FY27
The Gland Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Gland Pharma has already reported.
Valuation Snapshot
Gland Pharma trades at a price to earnings ratio of about 41.11 against trailing earnings per share of Rs 69.45, with the stock priced near Rs 2,855.2. Book value stands around Rs 629 per share, putting the price to book ratio at 4.54. Return on equity is a moderate 10.7 percent, typical of a capital-intensive injectable manufacturing business, while the dividend yield is modest at about 0.69 percent. The high earnings multiple relative to return on equity suggests the market is pricing in continued revenue and margin recovery beyond current reported levels.
Technical and Price Context
Gland Pharma shares trade around Rs 2,855.2, close to the 52-week high of Rs 3,042 and well above the 52-week low of Rs 1,573.6, placing the stock near the top of its annual range. The stock trades above both its 50-day moving average of Rs 2,460.76 and its 200-day moving average of Rs 1,914.91, indicating a sustained uptrend relative to its medium and longer-term trend lines. The relative strength index of 44.28 sits in neutral territory, suggesting the recent strong run has cooled somewhat without turning outright oversold.
Balance Sheet and Payout
Gland Pharma carries a debt to equity ratio of just 0.03, meaning the company operates with negligible borrowings, giving it substantial financial flexibility to fund capacity expansion and working capital largely through internal accruals. This near debt-free balance sheet reduces interest cost pressure on reported profit, distinct from the boost seen from the unusually high other income booked in March 2026. The dividend yield of about 0.69 percent reflects a modest but steady payout policy, consistent with a company still prioritizing reinvestment in its injectable manufacturing capacity over larger cash distributions to shareholders.
Gland Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print
Gland Pharma share price today is Rs 2,855.20 on the NSE, down Rs 40.30 or 1.39% from the previous close of Rs 2,895.50 on 16 September 2026, ahead of the Gland Pharma Q2 results announcement.
| Metric | Value (16 September 2026) |
|---|---|
| NSE Symbol | GLAND |
| Current Market Price | Rs 2,855.20 |
| 52-Week High | Rs 3,042.00 |
| 52-Week Low | Rs 1,573.60 |
| Market Capitalisation | Rs 47106 crore |
| PE Ratio | 41.11 |
| PB Ratio | 4.54 |
| EPS (TTM) | Rs 69.45 |
| Book Value per Share | Rs 629.00 |
| Debt to Equity | 0.03 |
| Return on Equity | 10.7% |
| 50-Day Moving Average | Rs 2460.76 |
| 200-Day Moving Average | Rs 1914.91 |
| RSI (14) | 44.28 |
The stock trades above both its 50-day average of Rs 2460.76 and its 200-day average of Rs 1914.91, with a 14-day RSI of 44.28. None of this is a view on where the shares go once the Gland Pharma Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Gland Pharma Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Gland Pharma Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Gland Pharma Q2 results print in proportion.
- Revenue against the Rs 1,487.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 184.00 crore in that same quarter
- Operating margin against 24.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Gland Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Gland Pharma Q2 Results FY27
The Gland Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Gland Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Gland Pharma Q2 results FY27 print faces a base of Rs 1,487.00 crore in revenue and a profit of Rs 184.00 crore, with the most recent quarter having delivered Rs 1,800.00 crore and a profit of Rs 317.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Gland Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Gland Pharma Q2 Results FY27
What is the Gland Pharma Q2 results date for FY27?
Ans. The Gland Pharma Q2 results date for FY27 is not confirmed. Gland Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Gland Pharma Q2 results 2026 cover?
Ans. The Gland Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Gland Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Gland Pharma Q2 results filing also carries the notes to the accounts.
What were the Gland Pharma Q1 FY27 results?
Ans. Gland Pharma Ltd. reported revenue of Rs 1,800.00 crore in Q1 FY27 and a profit of Rs 317.00 crore at the net level. Revenue was up 19.52% versus Q1 FY26 and net profit was up 47.44% from Rs 215.00 crore in Q1 FY26.
What were Gland Pharma Q2 FY26 results in the September 2025 quarter?
Ans. Gland Pharma Ltd. reported revenue of Rs 1,487.00 crore and a profit of Rs 184.00 crore in Q2 FY26. Operating margin was 21.0%. Those figures form the base for the Gland Pharma Q2 results FY27 comparison.
What are the main Gland Pharma Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Gland Pharma Q2 results expectations centre on revenue against the Rs 1,487.00 crore base, net profit against a profit of Rs 184.00 crore, operating margin against 24.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Gland Pharma share price today ahead of the Q2 earnings?
Ans. Gland Pharma share price is Rs 2,855.20 on the NSE as of 16 September 2026, down 1.39% from Rs 2,895.50. The stock is about 6.1% below its 52-week high of Rs 3,042.00 and 81.4% above its 52-week low of Rs 1,573.60, at a market capitalisation of Rs 47106 crore.
Is Gland Pharma a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Gland Pharma Ltd. The stock trades at a price-to-book ratio of 4.54 with a return on equity of 10.7%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
